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OBJECTIVE: The objective of this study was to compare
the McMaster’s Health Utilities Index-Mark III and the
EuroQol-5D in a surgical breast cancer population. 
METHODS: Seventy-five surgical breast cancer patients
participated in the study. The patients were given the
Mark III version of the Health Utilities Index (HUI), and
the EuroQol-5D (EQ) comprising both the classification
system and the thermometer at the same visit, and the or-
der of instrument administration was randomized. Infor-
mation on the age of the patient, the cancer stage, and
the number of comorbidities was obtained through chart
review. 
RESULTS: The mean age of patients was 60 (sd  10.7).
Ninety-six percent of the patients were diagnosed with ei-
ther stage I or II breast cancer. The majority of patients
had up to three comorbid conditions. The mean score on
the HUI was 84.6 (sd  16.8). The mean on the EQ clas-
sification system was 87.4 (sd  13.6), while that on the
EQ thermometer was 86.6 (sd  12.6). The correlation
coefficient between scores on the HUI and the EQ classi-
fication system was 0.54, while that between the HUI
and the EQ thermometer score was 0.66. Eight patients
(10.6%) recorded the highest score on the HUI, 36 patients
(48%) on the EQ classification system, while 12 patients
(16%) indicated “best imaginable health state” on the EQ
thermometer. The EQ classification system classified the
patients into 15 health states, while 33 health states on the
HUI classification system described the sample. 
CONCLUSION: The results of this study show that al-
though both the HUI and the EQ classification systems
are reliable measures of health status, they differ in terms
of instrument sensitivity to disease severity.
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OBJECTIVE: A retrospective claims analysis was per-
formed examining costs of care for breast cancer patients. 
METHODS: Two years of claims data (1/94 to 12/95)
were obtained from a provider of cancer care services to
managed care organizations. Patients with a breast cancer–
related medical claim (ICD-9 code of 174.X) were staged
according to the following criteria. Stage I: lumpectomy,
with no chemotherapy prior to or following lumpectomy,
and no ICD-9 code of 196.X; stage II: ICD-9 code of
196.3; stage III: ICD-9 code of 196.X, but not 196.3; stage
IV: ICD-9 code of 197, 198, or 199. Costs, reflecting the
amount reimbursed by the insurer, were calculated based
on medical and pharmacy resource utilization. Average pe-
riod costs were reported for each stage according to three
time frames: initial (6 months), maintenance (3 months),
and terminal (6 months). 
RESULTS: A total of 1822 female patients had a breast
cancer–related medical claim during this period; 530 pa-
tients were considered evaluable based upon available data.
Stage I patients had the lowest overall costs ($9572), while
stage IV patients experienced the highest overall costs
($34,448). Too few stage III patients (n  19) were identi-
fied to draw conclusions. Overall, highest costs were ob-
served during the terminal period. When data from all pa-
tients were analyzed, per-patient costs were $7183 over an
initial 6-month period, $3901 over a 3-month maintenance
period, and $12,080 over a 6-month terminal period. 
CONCLUSIONS: These results indicate that breast can-
cer patients in this setting utilized substantial medical re-
sources, particularly during the terminal phase of care,
and that utilization, in general, increased with stage.
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OBJECTIVE: The purpose of this study was to review
the HRQoL literature and to determine its usefulness for
assessing the impacts of alternative treatments for pa-
tients with prostate cancer. 
METHODS: A structured search was conducted of
widely available databases to identify studies of HRQoL
applied to prostate cancer, using the following inclusion
criteria: English language literature, original research,
peer-reviewed journal publication, inclusion of 10 or
more patients, and presence of a comparison group.
Manuscripts were analyzed for the type of HRQoL eval-
uated (generic versus disease-specific) prostate cancer–
related health domains analyzed, within- and between-
treatment HRQoL impacts, comparators used, and distri-
bution of studies across cancer stages and treatments. 
RESULTS: Over half (56%) of the 41 HRQoL studies as-
sessed the impact of single-treatment options without re-
gard to other available treatments; 44% compared two
or more therapies. Generic, non-disease-specific instru-
ments detected treatment-related changes in HRQoL in
2/15 (13%) instances. In contrast, 92% (11/12) of the
prostate cancer–specific instrument assessments detected
differences in HRQoL. Four of 14 reported prostate can-
cer–specific instruments are standardized and well vali-
Stage n
Initial
costs
Maintenance
costs
Terminal
costs
Total
costs
I 228 $4,169 $1,992 $3,411 $9,572
II 87 $6,371 $3,131 $5,176 $14,678
III 19 $637 $557 $7,905 $9,099
IV 196 $12,159 $5,602 $16,687 $34,448
All 530 $7,183 $3,901 $12,080 $23,164
